Tianjin Chase Sun pharmaceutical Co., Ltd. was established in 1996, and in 2009, it was one of the first batch of companies listed on the China Growth Enterprise Market. Its business covers six major sectors, including traditional Chinese medicine granules and processed materials, finished drug product, active pharmaceutical ingredient and excipients, medical devices, healthcare services, and smart supply chain solutions for MedTech industry.

Chase Sun values continuous technological innovation and research translation as the source of our prosperous development, with strong focuses on many therapeutic fields including critical care medicine, oncology, cardiovascular diseases, respiratory and inflammation, and neurodegenerative diseases.

In 2019, Chase Sun commenced operations in Australia as an important action of its strategic development plan and since then, we have been actively seeking collaboration with Australian partners.